Saturday, July 11, 2026

pharma · Influenza · Encephalitis, Japanese B

Repatha

Repatha is a pharma organization headquartered in JP. Primary therapeutic focus areas include Influenza, Encephalitis, Japanese B, Malaria, Vivax. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pate

JP HQ
PMDA registrant Type
Company details
Status
Public
HQ
JP
Programs
3
Drugs
6
Patents
0
Clinical program

IVACFLU

Phase 1 · mab · Influenza

IVACFLU for Influenza is a Phase 1 program (mab) at Repatha with 1 ClinicalTrials.gov record(s).

← All Repatha projects Phase 1 mab completed

Internal code IVAC-mH1N1-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Repatha
Phase
Phase 1
Modality
mab
Indication
Influenza
Status
completed
Trials
1